中国及全球女性乳腺癌流行病学特征分析
该研究利用GLOBOCAN 2022数据及Joinpoint趋势分析,描述全球与中国女性乳腺癌的发病、死亡及年龄分布特征,并预测2050年疾病负担。结果显示发病率随人类发展指数(HDI)升高而上升,中国负担低于全球均值但呈上升趋势,需加强防治。
要点
- 2022年中国女性乳腺癌ASIR为33.0/10万,ASMR为6.1/10万,均低于全球水平。
- 全球乳腺癌ASIR与HDI呈正相关(r=0.753,P<0.001)。
- 2002—2017年中国乳腺癌ASIR呈上升趋势,AAPC为2.00%(P<0.001)。
核心结论
- 女性乳腺癌疾病负担在全球不同地区和年龄组差异显著,发病率随HDI升高而升高。
- 中国乳腺癌疾病负担低于全球平均水平,但呈上升趋势,防治工作仍需加强。
研究设计与样本
- 基于GLOBOCAN 2022数据,按地区、年龄和HDI分组分析全球女性乳腺癌流行病学特征。
- 使用Spearman检验分析ASIR和ASMR与HDI的相关性。
- 使用Joinpoint 4.9.1.0软件对中国及部分国家历史发病率进行趋势分析,并预测2050年负担。
主要发现
- 2022年全球女性乳腺癌新发229.7万例,死亡66.6万例,ASIR为46.8/10万,ASMR为12.7/10万。
- 北美洲ASIR最高(95.1/10万),非洲ASMR最高(19.2/10万),亚洲ASIR和ASMR均最低(34.3/10万和10.5/10万)。
- 2022年中国女性乳腺癌新发35.7万例,死亡7.5万例,ASIR为33.0/10万,ASMR为6.1/10万。
- 全球年龄别发病率和死亡率高峰均在85+年龄组,中国发病率高峰在50~54岁和60~64岁年龄组。
- 2002—2017年中国、日本和韩国ASIR呈上升趋势,AAPC分别为2.00%、4.67%和5.08%(均P<0.001);美国AAPC为-0.16%(P=0.810)。
关键数值与推荐
- 极高HDI地区ASIR最高(75.6/10万),低HDI地区ASMR最高(19.0/10万)。
- 乳腺癌ASIR与HDI呈正相关(r=0.753,P<0.001),ASMR与HDI相关性无统计学意义(r=-0.101,P=0.106)。
- 预计2050年全球新发328.3万例、死亡112.0万例;中国新发38.8万例、死亡11.1万例。
- 与2022年相比,2050年低HDI地区发病和死亡数增幅最大(145.5%和149.8%),中HDI地区绝对值增加最多(27.9万例和15.8万例)。
临床怎么用
- 应结合HDI和年龄分布差异制定区域化乳腺癌防治策略。
- 中国乳腺癌负担虽低于全球均值但呈上升趋势,需持续加强早期筛查和防控措施。
- 低HDI地区未来发病和死亡增幅最大,应优先加强资源投入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the differences in the epidemiological characteristics and disease burden of breast cancer among women in different regions of the world and China, and to provide a theoretical basis for the implementation of relevant prevention and treatment measures. Methods: The epidemiological characteristics of female breast cancer in different regions and countries around the world were analyzed using relevant data from GLOBOCAN 2022, grouped according to region, age and human development index (HDI), and the differences in the epidemiological characteristics of female breast cancer in different regions and countries around the world were analyzed by using Spearman's test for the differences in the HDI and the age-standardized incidence rate (ASIR) and the age-standardized mortality rate (ASMR). The historical incidence rate data of China and some countries were analyzed for trends using Joinpoint 4.9.1.0 software, and the number of female breast cancer incidence and death were predicted for 2050. Results: In 2022, there were 2.297 million new cases of breast cancer and 666 thousand deaths worldwide among women. The global ASIR was 46.8/105, and the ASMR was 12.7/105. Among different geographical regions worldwide, North America had the highest ASIR of breast cancer (95.1/105); Africa had the highest ASMR (19.2/105); Asia had the lowest ASIR (34.3/105) and ASMR (10.5/105). In 2022, China reported 357 thousand new female breast cancer cases and 75 thousand deaths. China's ASIR was 33.0/105, and ASMR was 6.1/105. Regions with very high HDI had the highest ASIR (75.6/105). Regions with low HDI had the highest ASMR (19.0/105). Globally, the peaks of age-specific incidence rate and mortality rate of breast cancer were both in the 85+ age group. In China, the incidence rate peaked in the 50-54 and 60-64 age groups. A positive correlation was observed between breast cancer ASIR and HDI (r=0.753, P<0.001), while the correlation between ASMR and HDI was not statistically significant (r=-0.101, P=0.106). From 2002 to 2017, the ASIR of breast cancer showed an upward trend in China, Japan and Korea, with average annual percentage changes (AAPC) of 2.00%, 4.67% and 5.08% (all P<0.001). In contrast, the AAPC in the United States was -0.16%, and the trend was not statistically significant (P=0.810). By 2050, the global number of new breast cancer cases will reach 3.283 million, with 1.12 million deaths. In China, the number of new cases will be 388 thousand, with 111 thousand deaths. Compared with 2022, regions with low HDI will see the largest increases in the number of breast cancer cases (145.5%) and deaths (149.8%); regions with medium HDI will have the largest absolute increases in the number of cases (279 thousand cases) and deaths (158 thousand cases). Conclusions: The disease burden of female breast cancer varies significantly across different regions and age groups worldwide. The incidence rate increases with the rise of HDI. Currently, the disease burden of breast cancer in China is lower than that of the global average, but it shows an upward trend. Therefore, relevant prevention and control efforts need to be further strengthened. 目的: 探讨中国及全球部分地区女性乳腺癌流行特征和疾病负担差异,为相关防治措施落实提供理论依据。 方法: 利用GLOBOCAN 2022相关数据,根据地区、年龄和人类发展指数(HDI)等因素分组,分析全球不同国家或地区女性乳腺癌流行病学特征。使用Spearman检验分析乳腺癌标化发病率(ASIR)和标化死亡率(ASMR)与HDI的相关性。使用Joinpoint 4.9.1.0软件对中国及部分国家的历史发病率数据进行趋势分析,并预测2050年女性乳腺癌负担。 结果: 2022年全球女性乳腺癌发病数为229.7万例,死亡数为66.6万例;ASIR为46.8/10万,ASMR为12.7/10万。全球不同地理区域中,乳腺癌ASIR最高的是北美洲(95.1/10万),ASMR最高的是非洲(19.2/10万);ASIR和ASMR最低的均为亚洲(34.3/10万和10.5/10万)。2022年中国女性乳腺癌发病数为35.7万例,死亡数为7.5万例;中国ASIR为33.0/10万,ASMR为6.1/10万。极高HDI地区ASIR最高(75.6/10万),低HDI地区ASMR最高(19.0/10万)。全球年龄别发病率和死亡率高峰均在85+年龄组,而中国发病率高峰在50~54岁和60~64岁年龄组。乳腺癌ASIR与HDI呈正相关(r=0.753,P<0.001),ASMR与HDI相关性无统计学意义(r=-0.101,P=0.106)。2002—2017年,中国、日本和韩国的乳腺癌ASIR呈上升趋势,平均年度变化百分比(AAPC)分别为2.00%、4.67%和5.08%(均P<0.001),而美国AAPC值为-0.16%,趋势无统计学意义(P=0.810)。预计到2050年,全球乳腺癌新发病例将达到328.3万例,死亡112.0万例;其中中国新发38.8万例,死亡11.1万例。与2022年相比,2050年低HDI地区乳腺癌发病和死亡数增幅最大(145.5%和149.8%),中HDI地区乳腺癌发病和死亡数绝对值增加最多(27.9万例和15.8万例)。 结论: 女性乳腺癌在全球不同地区、不同年龄组疾病负担差异显著,发病率随HDI升高而升高。中国乳腺癌疾病负担低于全球平均水平,但呈上升趋势,相关防治工作仍需进一步加强。.
引用
- Xu YY, Zhang YH, Ding LL, et al. [Epidemiological characteristics of female breast cancer in China and worldwide]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41443734. doi:10.3760/cma.j.cn112152-20241127-00538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。